Correlation Between Thrombopoietin Serum Level and Liver Fibrosis in Chronic Hepatitis Patients by Sembiring, J. (Juwita)
Volume 11, Number  3,  December 2010 135
ORIGINAL ARTICLE
Correlation between Thrombopoietin Serum Level  
and Liver Fibrosis in Chronic Hepatitis Patients 
Juwita Sembiring
Department of Internal Medicine, Faculty of Medicine 
University of North Sumatera/Adam Malik Hospital, Medan
INTRODUCTION
Chronic hepatitis is a global problem at present 
because it frequently progresses to liver cirrhosis and 
hepatocellular carcinoma that commence with the 
process of fibrosis in the liver. Liver fibrosis results 
from chronic damage to the liver associated with 
excessive accumulation of extracellular matrix proteins. 
This accumulation will damage the architecture of the 
liver with fibrous connective tissue formation, which 
leads to the development of nodules. When the nodules 
are formed, the condition is called cirrhosis. The main 
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causes of liver fibrosis is a chronic infection from B 
and C viruses, alcohol drinking, and non-alcoholic 
steatohepatitis (NASH).1,2,3,4,5
Since fibrosis is known as the major problem 
causing morbidity and mortality in chronic liver 
disease, determining the degree of fibrosis is needed 
to provide early and correct treatment. Liver biopsy as 
an invasive method is still used as the gold standard 
in diagnosing the degree of fibrosis. Because many 
obstacles were experienced with this invasive method, 
many studies tried to diagnose the degree of fibrosis 
with noninvasive method.6,7,8,9,10
The difficulties faced are that the clinical picture is 
not always consistent with the degree of fibrosis and 
not all patients are willing to undergo a liver biopsy. 
Since there are many constraints in doing liver biopsy, 
especially not all places have adequate facilities, so we 
tried to find whether the determination of trombopoietin 
(TPO) could be used to predict the severity degree of 
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liver disease. TPO is a cytokine and also a hormone 
produced primarily by hepatocyte cells and a little in 
the kidney, spleen, lung, bone marrow, and brain. TPO 
strongly induces the proliferation of megakaryocyte 
(MK). It has been identified as a hormone that controls 
trombopoiesis.11 TPO is still a relatively new discovery 
that its utilization must be developed.
This study aimed to obtain data on the correlation 
of serum TPO levels with the degrees of liver fibrosis 
and to ascertain whether serum levels of TPO can be 
used as an alternative to determine the degree of liver 
fibrosis in patients with chronic hepatitis.
METHOD
This study used an analytical cross sectional study 
design to examine the relationship between serum 
TPO levels and degrees of liver fibrosis in 62 patients 
with chronic hepatitis from June 2006 to March 
2008. Screening of patients was conducted at several 
hospitals in Medan and Jakarta.
Histopathologic tissue examinations by liver 
biopsy were done on patients to verify the degree of 
fibrosis in accordance to Metavir system score in each 
patient with chronic hepatitis.12,13,14 Blood samplings to 
establish the levels of serum TPO were accomplished 
by Quantikine Human TPO immunoassay. We then 
performed statistical analysis with Spearman’s 
correlation test to assess the relationship of serum 
TPO levels and severity degrees of liver damage 
(fibrosis). Furthermore, the sensitivity and specificity 
of TPO in diagnosing the degree of liver fibrosis can 
be determined.15,16
RESULTS
From a number of 62 samples, only 55 patients met 
the inclusion criteria, which consisted of 22 female and 
33 male with an age range of 18-70 years old. A total 
of 38 patients suffered from hepatitis B, 15 patients 
from hepatitis C, and 2 patients from non B & non 
C hepatitis. This study also included 11 people from 
the normal group and 10 patients with liver cirrhosis.
The calculation above shows that no significant 
difference was found on the sex, age and hepatitis virus 
type between the fibrosis groups (p < 0.79). In figure 
1 there was difference in the TPO levels starting from 
second-degree fibrosis and higher (F2 > F1, F3 < F2). 
Figure 2 shows no significant difference in age.
Table1. Clinical characteristics of subjects at baseline
Characteristic
Hepatitis types (mean ± SD)
B (n = 38) C (n = 15) non B & non C (n = 2) p
Age (year) 42.05 ± 10.46 41.20 ± 15.90 44.00 ± 28.28 0.949
AST 57.83 ± 39.47 77.80 ± 57.53 71.00 ± 51.33 0.350
ALT 71.01 ± 51.20 91.87 ± 83.96 105.50 ± 98.29 0.458
Thrombopoetin 23.98 ± 17.46 20.84 ± 16.50 15.00 ± 2.02 0.672
Platelets 192,052.63 ± 46,286.39 170,333.30 ± 62,782.69 139,500,00 ± 74,246.21 0.190
Table 2. Demographics of sex, age and type of hepatitis at various degrees of fibrosis
Fibrosis degree F1 F2 F3 F4
Sex
      Female 1/33.3% 8/34.8% 11/50.0% 2/28.6%
      Male 2/66.7% 15/65.2% 11/50.0% 5/71.4%
Age (year) 46.3 ± 10.2 41.4 ± 14.5 42.1 ± 9.7 41.0 ± 16.1
Types of hepatitis
B (n : 38) 3/100% 15/65.2% 18/81.8% 2/28.6%
C (n : 15) - 7/30.4% 4/18.2% 4/57.1%
Non B and non C (n : 2) - 1/14.4% - 1/14.3%
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Table 3 shows that the difference in the TPO level 
started at second-degree fibrosis and higher. The result 
of different levels testing on the six groups above, 
with analysis of variance (ANOVA), also showed 
a significant difference in levels, i.e. p = 0.047. 
To get the cut off value of TPO levels that provide the 
highest sensitivity and specificity, receiver operating 
characteristics (ROC) analysis was done. 
The area under the curve, as big as 0.302, is very 
significant (p = 0.003), different from 0.5 (95% 
confidence interval 0.184 - 0.421). By multiplying 
the sensitivity with the highest specificity, a cut-off 
16.01 was obtained. At this value, the specificity and 
sensitivity of TPO were 64.1% and 70.3% respectively. 
Chi-square Pearson test results showed a highly 
significant association between decreased levels of 
TPO and second-degree fibrosis or higher (p = 0.003).
Figure 2. Plot of age groups at various degrees of fibrosis
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Table 3. TPO levels of the normal group at various degrees 
of fibrosis and cirrhosis
Degree of fibrosis 
and cirrhosis n Mean ± SD
Normal 11 96.3 ± 178.9
F1 3 16.4 ± 10.2
F2 23 29.0 ± 18.7
F3 22 20.8 ± 15.1
F4 7 11.1 ± 10.0
Cirrhosis 10 10.2 ± 12.2
Table 4. Number of cases for fibrosis degree F ≤ 2 and 
fibrosis degree F > 2
Fibrosis groups
Group F ≤ 2     Group F > 2            
(normal, F1, F2) (F3, F4, cirrhosis)
37 patients 39 patients
The analysis concluded that there were 37 patients 
with second-degree fibrosis or less (normal, F1, F2) 
and 39 patients with higher than second-degree fibrosis 
(F3, F4 or cirrhosis).
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Figure 3. ROC analysis shows the specificity and sensitivity of TPO
Table 5. Cross tabulation between the cut-off levels of TPO 
with the degrees of fibrosis
Fibrosis groups
Fibrosis degree
Total
F ≤ 2 F > 2
Levels of TPO 
≥ 16.01 pg/ml 26 (70.3%) 14 (35.9%) 40 (52.6%)
< 16.01 pg/ml 11 (29.35%) 25 (64.1%) 36 (47.4%)
Total 37 (100%) 39 (100%) 76 (100%)
Positive predictive value (TPO < 16.01 pg/ml) = (25 / 25 + 11) x 100% = 69.4% 
Negative predictive value (TPO > 16.01 pg/ml) = (26/26+14) x 100% = 65.0%
Table 6 shows that the correlations between TPO 
with AST, ALT, AST/ALT, ALT/AST, and platelets 
were not significant (p > 0.05), while the correlation 
of TPO with the degree of fibrosis was significant (p 
Table 6. Correlation between TPO with the degree of 
fibrosis, AST, ALT and platelets
Variabels correlation r p
AST -0.63 0.648
ALT -0.42 0.762
AST/ALT -0.197 0.150
ALT/AST 0.197 0.150
Degree of fibrosis -0.284 0.036 *
Platelets 0.217 0.112
Table 7. The correlation between the degree of fibrosis, 
AST, ALT and platelets
Variables correlation r p
AST 0.284* 0.036
ALT -0.037 0.791
AST/ALT 0.427** 0.001*
ALT/AST -0.427** 0.001*
Platelets -0.783** 0.001*
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Figure 1. Plot of the normal group TPO levels in various degrees 
of fibrosis and cirrhosis
Cirrhosis
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< 0.05). This shows that the smaller TPO level, the 
greater the degree of fibrosis.
Table 7 shows that the correlation between 
the degree of fibrosis and AST, and ALT were not 
significant (p > 0.05), though the correlation coefficient 
between the degree of fibrosis with AST = 0.284. 
Meanwhile the degree of fibrosis correlated with 
the ratio of AST/ALT, ALT/AST and platelets were 
significant (p < 0.05).
In figure 6 it is noted that the line that formed showed 
positive relationship trait, where if the platelet count 
increases, the TPO level increases.
From the results of Spearman’s correlation test, it 
was found that levels of TPO have a very significant 
negative correlation with the degrees of liver fibrosis 
(r = -0.284; p < 0.05). At the cut-off 16.01 pg/mL, 
the sensitivity and specificity of TPO in diagnosing 
the degree of fibrosis greater than F2 (F3 or greater) 
is obtained, i.e. 64.1% and 70.3% respectively. 
If the TPO concentration is less than 16.01 pg/mL, 
it is significantly associated (p = 0.003) with F3, F4 or 
cirrhosis of the liver. In addition, there were significant 
differences between the degrees of fibrosis and 
platelet counts (F1 : 222,000 ± 26,153; F2 : 223,590 ± 
35,000; F3 : 170,681 ± 19,948; F4 : 990,000 ± 43,464; 
< 0.0001). A significant negative correlation between 
the degrees of fibrosis and platelet levels (r = -0.783; 
p = 0.001) was also found. Thus, the more severe 
the degree of fibrosis, the lower the platelet counts.
DISCUSSION
Liver fibrosis results from chronic damage to 
the liver associated with excessive accumulation of 
ECM proteins. It can be found in many types of chronic 
liver diseases. Accumulation of ECM proteins would 
damage the architecture of the liver with the formation 
of fibrous connective tissue and the development of 
nodules. When the nodules had formed, the condition is 
called cirrhosis. Liver fibrosis is described as a wound 
healing response to chronic liver injury.8
In chronic liver disease, chronic liver injury occurs, 
causing decreased production of TPO. TPO levels in 
patients with chronic hepatitis and cirrhosis of the 
liver decreased in accordance with the severity of 
the liver disease. This occurs due to the inadequate 
TPO production in patients who experience severe 
necroinflammation activity.17,18,19 In chronic liver 
disease, hematological disorders in the form of 
thrombocytopenia is also frequently found but the 
mechanisms of pathogenesis is still not perfectly 
known.19
Table 8. The number of platelets in patients with chronic 
hepatitis with different degrees of fibrosis
Fibrosis degree n Platelets (mean ± SD)
F1 3 222.000 ± 26.153
F2 23 223.591 ± 35.000
F3 22 170.682 ± 19.948
F4 7 99.000 ± 43.464
Differences of platelets for each degree of 
fibrosis were significantly different (p = 0.0001). In 
the ANOVA test, there were significant differences 
between the degree of fibrosis and the mean platelet. 
The differences were the F1 degree of fibrosis 
compared with F3, F1 with F4, F2 with F3, and F2 
with F4. It can be seen in figure 4 that the line formed 
shows a negative relationship trait; that is when the 
TPO levels declines, the degree of fibrosis increases. 
In figure 5, it is known that the line formed shows 
a negative relationship trait, where if the degree of 
fibrosis increases, the number of platelets decreases. 
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Figure 4. Linear regression curves indicates if TPO levels declines, 
the degree of fibrosis increases
00001.05315.4 −=iy
Platelet count (/mm )3
D
eg
re
e 
of
 fi
br
os
is
Figure 5. Linear regression curve indicates if the degree of fibrosis 
increases, platelet count decreases
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Figure 6. Linear regression curve indicates if the platelet count 
increases, the level of TPO increases
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Through this study, it was noted that the development 
of hepatic fibrosis might cause disruption to the 
production of TPO and subsequently, cause a reduction 
in the number of platelets. This is consistent with 
Afdal et al who reported that the decrease of TPO 
synthesis correlates with the progression of chronic 
liver disease.20 In Medan, Ginting had measured the 
serum TPO levels in patients with liver cirrhosis.21
In this study, the 55 patients who fulfilled the 
inclusion criteria consisted of 38 patients with hepatitis 
B, 15 patients with hepatitis C 15 and 2 patients with 
non B and non C hepatitis. It is visible that in the 
community the rejection rate to participate in a study 
was still high compared with the high prevalence of 
chronic hepatitis in Indonesia. Because biopsy is an 
invasive method, the measurement of serum TPO 
levels in determining the severity of liver damage is 
more acceptable due to its non-invasive methods.
No significant difference in sex, age and type of 
hepatitis virus between groups of fibrosis was shown in 
this study. This is in accordance with previous studies 
because the risk of getting hepatitis can be found in any 
age group regardless of sex differences (tables 2 and 3).
Some studies on the relationship between TPO 
levels and degrees of severity of liver disease have 
been reported and is still controversial. Studies which 
supports the idea that levels of serum TPO decreases 
in accordance with the severity degree of liver disease 
(fibrosis) were reported by Goulis et al, Wien et al, 
Koruk et al, Adinolfi et al.12,17,18,19 The results of other 
studies which do not support reduced levels of serum 
TPO is in accordance with the degree of severity of 
liver disease (fibrosis) were reported by Freni et al, 
Schoffski et al, Shi  et al.22,23,24
TPO levels will decrease in conformity with 
increase in the severity of liver damage characterized 
by the degree of fibrosis through liver biopsy. In this 
study it is shown that with more severe degree of liver 
damage serum TPO level will decline progressively, 
TPO levels in healthy people, F1, F2, F3, F4 and 
cirrhosis: 96.3 ± 178.9 (normal); 16, 4 ± 10.2 (F1); 
29.0 ± 18.7 (F2), 20.8 ± 15.1 (F3); 11.1 ± 10.0 (F4) and 
10.2 ± 12.2 (cirrhosis) consecutively (table 3). This is 
consistent with previous study and further strengthen 
that TPO is synthesized in the liver. So if there is 
damage to the liver, the level will decrease further. 
TPO level also inverses with the degrees of fibrosis.
In figure 1 it was found that serum TPO levels in 
F1 is lower than in F2 and F3. This is possible because 
TPO is produced in hepatocytes cells, but the regulation 
is in the circulation (peripheral). TPO has a receptor 
on megakaryocytes and platelets. If TPO binds to 
receptors on the platelets, TPO will be destroyed by 
platelets (down regulation), whereas when bound 
to receptors on megakaryocyte, TPO will stimulate 
megakaryocyte to form platelets. 
TPO is a cytokine as well as a hormone, which 
molecularly its reaction to the receptors of different 
cells is not equal. This could occur due to different 
signal transduction depending on its receptors. This 
condition causes the possibility of lower serum TPO 
levels in F1 than in the F2 and F3. 
Statistically significant difference was seen between 
TPO levels in F2 and cirrhosis (p = 0.03) whereas 
the difference between F2 and F4 is on the borderline 
(p = 0.053). This is probably due to the relatively 
small number of samples in the group of F4 in this 
study. Ideally the numbers of samples in each sample 
population subgroups are the same (homogeneous).
The study involved several national and regional 
referral center hospitals, where in a relatively long 
time the number of cases found was still small (55 
cases), despite evidence that showed that TPO levels 
is inversely proportional to the staging of fibrosis. 
Because of that it is necessary to find limits TPO 
levels that can be used as a cut off value to determine 
the degree of chronic hepatitis fibrosis. In this study, 
with TPO levels 16.01 pg/mL, the sensitivity was 
64.1%, specificity 70.3%, positive predictive value 
69.4% and negative predictive value 65%. These 
values were high enough when compared to the gold 
standard, which has limitations. It was also noted that 
the cut-off value 16.01 pg/mL can distinguish whether 
patients has a more severe degree of liver damage 
or not. If the value of TPO < 16.01 pg/mL, the liver 
damage is more severe (F3 or greater) and cirrhosis 
may occur (F4). If levels of TPO > 16.01 pg/mL, then 
the liver damage is lighter (normal, F1 or F2). From this 
study, a significant negative correlation between the 
degrees of fibrosis and platelet was obtained (p < 0.05; 
r = -0.783) and a positive correlation between the ratio 
of AST/ALT with the degree of fibrosis (r = 0.427; 
p = 0.001) was found. Thus, this result is a new finding, 
that by measuring serum TPO levels we can determine 
whether a person is suffering from chronic hepatitis, 
especially with the higher than F2 degree of fibrosis. 
In previous study, there has not been any that tells us the 
cut-off levels of TPO in determining chronic hepatitis. 
From the results of a study on chronic hepatitis 
patient groups with F1 to F4 degrees of fibrosis and 
cirrhosis, a negative correlation to serum TPO levels 
(r = -0.284; p = 0.036) was found (table 6), which 
indicates that if the degree of liver fibrosis increases, 
the levels of  serum TPO decreases. This is consistent 
with a study conducted by Adinolfi et al.12 In this study, 
TPO levels were found significantly different on the 
second degree fibrosis (F2) compared with forth degree 
(F4) with p = 0.001. Kaushansy et al reported that age 
did not affect the levels of TPO.11 This situation can be 
explained because TPO is synthesized in the liver and 
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the level will decrease if there is an increasingly severe 
liver injury. Until now the gold standard in assessing 
the degree of liver fibrosis is by liver biopsy, which is 
invasive. It is necessary to determine the degree of liver 
fibrosis in patients with chronic hepatitis especially 
B and C viruses, with the aim to initiate, evaluate the 
treatment and determine the prognosis of the disease.
Although some previous study has been done 
abroad, the determination of a cut-off value of TPO 
for its usage in determining the severity degree of liver 
disease does not exist, even though the determination 
of a cut-off value can then be used to determine 
the severity degree of liver disease or in assessing 
the success of treatment of chronic liver diseases. 
The study found that by using a cut-off value 16.01 
pg/mL we will be able to distinguish whether a patient 
has a more severe degree of liver damage or not. If the 
value of TPO < 16.01 pg/mL, it indicates that the liver 
damage was relatively severe, the patient has third 
degree of fibrosis (F3) minimum. Meanwhile, when 
the level of TPO > 16.01 pg/mL, it indicates that the 
patient is suffering from liver disease with the first (F1) 
or second (F2) degree of fibrosis or even a non-chronic 
hepatitis. Ideally this cut-off value should be able to 
determine the F2 degree because chronic hepatitis 
caused by hepatitis B or C virus will begin treatment at 
F2 degree. In this study it cannot be employed because 
of the small sample size and the inhomogeneous data 
distribution. However, the cut-off value 16.01 pg/mL 
can actually be used to evaluate the degree of severity 
and the therapy of chronic hepatitis because with 
the cut-off value < 16.01 pg/mL, F3, F4 degrees and 
cirrhosis can be determined.
TPO is a hormone produced by the liver, which 
function to stimulate the formation of platelet. 
This statement was frequently mentioned in previous 
researches.18,19 However, a significant correlation 
between the levels of TPO and platelet counts 
(p > 0.05) was not shown. Platelet levels in patients 
with chronic hepatitis were inversely proportional to 
the degree of fibrosis (F1-F4).
The fact is all this time in patients with chronic 
hepatitis or cirrhosis, decrease in platelets was 
proportional to the severity of liver damage, especially 
in patients with hepatitis C, although lower levels of 
platelets showed no severe thrombocytopenia that 
causes spontaneous bleeding (platelets < 10,000/mm3) 
or risk of bleeding with invasive measures (platelet 
20,000-50,000/mm3). Decrease in platelet count in 
patients with chronic hepatitis addresses the need for 
vigilance for risk of bleeding caused by rupture of 
varicose veins in liver cirrhosis. In this study a very 
significant difference between the degree of liver 
damage and platelet counts (p = 0.0001) was noted.
This study found that serum TPO levels negatively 
correlated with the degree of severity of liver fibrosis 
(p = 0.036; r = -0.284) and positively correlated 
with levels of platelets (p = 0.112; r = 0.217). 
Thrombocytopenia can occur if the number of 
platelets in the blood < 100,000/mm3. This is a 
common complication of chronic liver disease, but 
the pathogenesis is not clear. It is estimated that the 
congestion of the spleen is due to portal hypertension 
(which is the main etiological factor), increased 
destruction of platelets, decreased production of 
platelets and anti-platelets antibodies, the occurrence of 
disseminated intravascular coagulation, translocation 
of toxin or substances derived from the gastrointestinal 
tract, and portosystemic shunting.25
Important observation in some previous studies 
illustrated that TPO plays a major role in regulating 
platelet production physiologically. TPO levels 
decreased in patients with chronic hepatitis and 
cirrhosis. TPO mRNA levels in the liver tissue 
decreased with progressive liver disease in humans 
and mice. TPO levels increased significantly after 
liver transplantation and then perfect resolution of 
thrombocytopenia occurred after transplantation. All 
this supports that thrombocytopenia in chronic liver 
disease is not only due to splenic sequestration, but 
also because of reduced production of platelets due to 
decreased synthesis of TPO.15,25-31
Some researchers reported the correlation of 
peripheral platelet count with the severity degree of 
fibrosis in patients with chronic hepatitis C. More 
recently researchers have also reported the same 
result on people with chronic hepatitis B. Their 
study of patients with chronic hepatitis B and C 
demonstrated a decrease in peripheral platelet counts 
that correlate with liver injury. Peripheral platelet 
count correlated negatively with the fibrosis score 
and necroinflammatory activity (NIA). Treatment of 
hepatitis C virus infection progressed much since the 
introduction of combination therapy of interferon and 
ribavirin. Many factors affect the response to treatment 
including histological stage of disease. Patients with 
severe fibrosis or cirrhosis at the time of diagnosis 
failed to give good treatment results and more often 
end up with advanced-stage liver disease compared 
with patients without severe fibrosis.15,25,26
Consensus of National Institutes of Health 
recommends performing a liver biopsy before starting 
treatment.32 With so many obstacles or difficulties in 
doing a liver biopsy, many efforts were made to avoid 
this invasive liver biopsy. A simple non-invasive 
laboratory method that can predict the degree of 
fibrosis can be used as an alternative to lessen liver 
biopsy before physicians provide treatment to patients 
with chronic hepatitis. Some researchers tried to use 
aminotransferase ratio, which is sometimes combined 
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with other laboratory parameters to predict severe 
liver fibrosis or cirrhosis, but the results are still 
controversial. For aminotransferase itself, its positive 
predictive value is still quite low. Other researchers 
estimate that the number of platelets may be associated 
with fibrosis.
In studies conducted by Pohl et al and Shin et al 
predicting cirrhosis using the ratio of AST/ALT in 
evaluating the starting point of patients with hepatitis 
C virus infection was attempted.33,34 It was reported 
that the ratio of AST/ALT and platelet count correlated 
with the degree of fibrosis in patients without history 
of excessive alcohol drinking. The combination of 
the ratio of AST/ALT ≥ 1 and platelet count ≤ 150,000/
mm3 can detect patients with severe fibrosis (grade 3 
and 4) positively with high predictive value (93.1%) 
and specificity (99.1%).33
In this study, Spearman’s correlation test was 
also done between the degree of liver fibrosis and 
the ratio of AST/ALT and results that correlated 
positive significantly (p = 0.001; r = 0.427) was 
obtained. If the ratio of AST/ALT is greater, then 
the degree of liver fibrosis magnifies. The discovery 
of fibroscan, which is a novel non-invasive imaging 
to measure the degree of fibrosis, when connected 
or combined with examination of serum TPO levels 
produce higher sensitivity and specificity.
In addition, it is found that serum TPO levels 
negatively correlated with the severity degree of 
liver fibrosis and positively correlated with levels of 
platelets. Moreover, a positive correlation between 
the degree of liver fibrosis with the ratio of AST/ALT 
was found.
CONCLUSION
A significant negative correlation between serum 
TPO levels and the degree of liver fibrosis in patients 
with chronic hepatitis, in which serum TPO levels with 
the cut-off 16.01 pg/mL can diagnose the F3 degree or 
greater, was found. A significant negative correlation 
between the degree of fibrosis and platelet levels was 
also noted.
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